Raising the Bar for Clinical Cardiac Troponin Research Studies and Implementation Science

Abstract

Over the past 3 decades, cardiac troponin (cTn) I and T have evolved as the preferred biomarkers for the detection of myocardial injury and in the appropriate setting to support the diagnosis of acute myocardial infarction (MI).1 Almost all of the early data in this field were derived from observational studies including multiple key secondary analyses from acute coronary syndrome trials supporting their use.2 Over time, analytic advancements brought by high-sensitivity (hs) cTn assays enabled the reliable measurement of very low cTn concentrations that allowed the development of various MI risk stratification approaches.